Atezolizumab for untreated PD-L1 positive locally advanced or metastatic urothelial cancer when cisplatin is unsuitable (CDF review TA492): a single technology appraisal

Cooper, Keith, Pickett, Karen, Ribeiro, Ines, Scott, David Alexander and Shepherd, Jonathan (2021) Atezolizumab for untreated PD-L1 positive locally advanced or metastatic urothelial cancer when cisplatin is unsuitable (CDF review TA492): a single technology appraisal (Health Technology Assessment, HTA - NIHR131842) National Institute for Health and Care Research 60pp.

Record type: Monograph (Project Report)

Abstract

This report is a critique of the company’s submission (CS) to the NICE Cancer Drugs Fund (CDF) review of TA492 on the clinical effectiveness and cost effectiveness of atezolizumab for untreated PD-L1 positive locally advanced or metastatic urothelial cancer when cisplatin is unsuitable.

Text

Atezolizumab ERG report

Download (1MB)

More information

Published date: 2021

Related URLs:

https://www.journalslibrary.ni...R131842/#/

Identifiers

Local EPrints ID: 454377

URI: http://eprints.soton.ac.uk/id/eprint/454377

PURE UUID: c43a4d2e-f90d-40b9-ab46-84d8542bdce4

ORCID for Keith Cooper:

orcid.org/0000-0002-0318-7670

ORCID for Karen Pickett:

orcid.org/0000-0002-8631-6465

ORCID for Ines Ribeiro:

orcid.org/0000-0001-8464-4513

ORCID for David Alexander Scott:

orcid.org/0000-0001-6475-8046

ORCID for Jonathan Shepherd:

orcid.org/0000-0003-1682-4330

Catalogue record

Date deposited: 08 Feb 2022 17:42

Last modified: 10 Apr 2024 02:03

Export record

Share this record

Share this on Facebook Share this on Twitter Share this on Weibo

Contributors

Author: Keith Cooper

Author: Karen Pickett

Author: Ines Ribeiro

Author: David Alexander Scott

Author: Jonathan Shepherd

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Library staff additional information